Use of Continuous-Infusion Ceftolozane/Tazobactam in a Multidrug-Resistant Pseudomonas aeruginosa Urinary Tract Infection in the Outpatient Setting

Abstract

Get full access to this article

View all access options for this article.

References

Liscio

Mahoney

Hirsch

EB.

Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2015;46:266-271.

Buck

Bertram

Ackermann

. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents. 2005;25:62.

Nateson

Pai

Lodise

TP.

Determination of alternative ceftolozane/tazobactam (C/T) dosing regimens for patients with infections due to Pseudomonas aeruginosa with high (C/T) MIC values. Poster presented at: Antimicrobial Pharmacokinetics and Pharmacodynamics, IDWeek 2016; October 26-30; New Orleans, LA.

FDA decision summary for ceftolozane/tazobactam. http://www.accessdata.fda.gov/cdrh_docs/reviews/K150556.pdf. Accessed October 18, 2016.